Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results

June 25, 2024

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL launched and commercial sales ongoing

Funding commitments from U.S. Air Force Academy intended to advance ATI-1701 toward an IND submission to the FDA

Read more at globenewswire.com

Related news for (APLIF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.